Prosecution Insights
Last updated: November 04, 2026
Application No. 18/989,081

METHOD FOR LOWERING CHOLESTEROL AND LIPID LEVELS USING THE ANTRODIA CINNAMOMEA WATER-INSOLUBLE DIETARY FIBER

Non-Final OA §112
Filed
Dec 20, 2024
Priority
Mar 02, 2020 — CN 202010135376.9 +2 more
Examiner
HOFFMAN, SUSAN COE
Art Unit
1655
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
University Of Shanghai For Science And Technology
OA Round
1 (Non-Final)
54%
Grant Probability
Moderate
1-2
OA Rounds
1y 1m
Est. Remaining
80%
With Interview

Examiner Intelligence

Grants 54% of resolved cases
54%
Career Allowance Rate
591 granted / 1091 resolved
-5.8% vs TC avg
Strong +26% interview lift
Without
With
+25.7%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
65 currently pending
Career history
1175
Total Applications
across all art units

Statute-Specific Performance

§101
10.5%
-29.5% vs TC avg
§103
35.5%
-4.5% vs TC avg
§102
15.2%
-24.8% vs TC avg
§112
27.6%
-12.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1091 resolved cases

Office Action

§112
DETAILED ACTION 1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . 2. Claims 8-14 are currently pending. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 8-14 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. 3. Claim 8 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being incomplete for omitting essential steps, such omission amounting to a gap between the steps. See MPEP § 2172.01. The omitted steps are: the claim states that it is drawn to a method for lowering cholesterol and lipid levels using Antrodia cinnamomea water-insoluble dietary fiber. However, the claim is missing the key step where the fiber is administered to a subject to achieve the desired effect. Applicant must amend the claim to include a step of administering the fiber to a subject. 4. Claims 9-14 are indefinite because they depend from cancelled claim 1. Allowable Subject Matter 5. Claims 8-14 would be allowable if rewritten or amended to overcome the rejection(s) under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), 2nd paragraph, set forth in this Office action. Claims 8-14 are considered to be free of the art. The closest prior art is Yu (CN 109223837 – English translation). This reference teaches using fiber extracted from Antrodia cinnamomea to lower cholesterol. However, the reference does not teach that the fiber is a water insoluble dietary fiber produced according to the process steps recited in claim 8. The reference teaches that the fiber is produced by water extraction and drying (see translation). According to applicant’s specification, the insoluble fiber produced according to the method of claim 8 has a purity of at least 68.5% (see paragraph 42). The reference does not teach using a water insoluble fiber with this degree of purity and there is no specific reason to believe that the water extraction taught by the reference would produce a water insoluble fiber with this degree of purity. Therefore, the claims are considered to be free of the prior art. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Susan Hoffman whose telephone number is (571)272-0963. The examiner can normally be reached M-Th 8:30am - 5:00pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Anand Desai can be reached at 571-272-0947. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SUSAN HOFFMAN/Primary Examiner, Art Unit 1655
Read full office action

Prosecution Timeline

Dec 20, 2024
Application Filed
Oct 29, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12779000
Processes for Extracting Muscimol from Amanita Muscaria
3y 1m to grant Granted Nov 03, 2026
Patent 12766178
SKIN CLARIFIER
5y 0m to grant Granted Oct 20, 2026
Patent 12766176
DEBITTERING KUDINGCHA EXTRACT, PREPARATION METHOD AND FINGERPRINT DETECTION METHOD THEREOF
3y 8m to grant Granted Oct 20, 2026
Patent 12766180
Fagopyrum Nutraceutical Compositions
2y 7m to grant Granted Oct 20, 2026
Patent 12758602
ANTI-INFLAMMATORY COMPOSITION COMPRISING EPIMENDIUM KOREANUM NAKAI, POLYGALA TENUIFOLIA WILD, AND POLYPORUS UMBELLATUS FRIES EXTRACTS OR MIXTURE THEREOF AS ACTIVE INGREDIENT
3y 1m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
54%
Grant Probability
80%
With Interview (+25.7%)
2y 11m (~1y 1m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1091 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month